Phase I study of HeFi-1 [monoclonal antibody HeFi-1] in refractory CD30-positive malignancy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Monoclonal antibody HeFi-1 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 02 Jul 2017 Biomarkers information updated
- 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Feb 2010 Actual end date (Jul 2008) and actual number of patients (9) added as reported by ClinicalTrials.gov.